College of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China.
State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.
Fitoterapia. 2014 Jan;92:34-40. doi: 10.1016/j.fitote.2013.09.016. Epub 2013 Oct 3.
The total flavonoids (TFs) were isolated from the leaves of Carya cathayensis Sarg. (LCC), a well-known Chinese medicinal herb commercially cultivated in Tianmu Mountain district, a cross area of Zhejiang and Anhui provinces in China. Five flavonoids, i.e. cardamonin, pinostrobin chalcone (PC), wogonin, chrysin, and pinocembrin were the main components of the TFs. The TFs and these pure compounds suppressed vascular endothelial growth factor (VEGF)-induced angiogenesis as detected in the mouse aortic ring assay, and cardamonin showed the best effect among them. To further elucidate the mechanisms for suppressing angiogenesis of these flavonoids, assays of VEGF-induced proliferation and migration in human umbilical vein endothelial cells (HUVECs) were performed. The TFs, cardamonin, pinocembrin, and chrysin obviously suppressed both VEGF-induced HUVEC proliferation and migration. However, PC and wogonin not only slightly inhibited VEGF-induced proliferation but also remarkably suppressed those of migration in HUVECs. Our further study showed that cardamonin decreased the phosphorylation of ERK and AKT induced by VEGF with a dose-dependent manner in HUVECs. Our findings indicate that the TFs and these pure flavonoids may become potential preventive and/or therapeutic agents against angiogenesis-related diseases.
总黄酮(TFs)从中国浙皖交界的天目山地区商业化种植的山核桃(Carya cathayensis Sarg.)叶中分离得到。五种黄酮类化合物,即小豆蔻明、松脂素查尔酮(PC)、白杨素、白杨素和乔松素是 TFs 的主要成分。TFs 和这些纯化合物抑制了血管内皮生长因子(VEGF)诱导的血管生成,如在小鼠主动脉环实验中所检测到的,其中小豆蔻明效果最好。为了进一步阐明这些黄酮类化合物抑制血管生成的机制,对人脐静脉内皮细胞(HUVECs)中 VEGF 诱导的增殖和迁移进行了检测。TFs、小豆蔻明、乔松素和白杨素明显抑制了 VEGF 诱导的 HUVEC 增殖和迁移。然而,PC 和白杨素不仅轻微抑制了 VEGF 诱导的增殖,而且明显抑制了 HUVECs 中的迁移。我们的进一步研究表明,小豆蔻明以剂量依赖性方式降低了 VEGF 诱导的 HUVEC 中 ERK 和 AKT 的磷酸化。我们的研究结果表明,TFs 和这些纯黄酮类化合物可能成为抗血管生成相关疾病的潜在预防和/或治疗药物。